Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour - PubMed (original) (raw)

Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour

D Astuti et al. Br J Cancer. 2005.

Abstract

Epigenetic alterations in the 11p15.5 imprinted gene cluster are frequent in human cancers and are associated with disordered imprinting of insulin-like growth factor (IGF)2 and H19. Recently, an imprinted gene cluster at 14q32 has been defined and includes two closely linked but reciprocally imprinted genes, DLK1 and GTL2, that have similarities to IGF2 and H19, respectively. Both GTL2 and H19 are maternally expressed RNAs with no protein product and display paternal allele promoter region methylation, and DLK1 and IGF2 are both paternally expressed. To determine whether methylation alterations within the 14q32 imprinted domain occur in human tumorigenesis, we investigated the status of the GTL2 promoter differentially methylated region (DMR) in 20 neuroblastoma tumours, 20 phaeochromocytomas and, 40 Wilms' tumours. Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. Analysis of neuroblastoma cell lines revealed that GTL2 DMR hypermethylation was associated with transcriptional repression of GTL2. These epigenetic findings are similar to those reported in Wilms' tumours in which H19 repression and DMR hypermethylation is associated with loss of imprinting (LOI, biallelic expression) of IGF2. However, a neuroblastoma cell line with hypermethylation of the GTL2 promoter and intergenic DMR did not show LOI of DLK1 and although treatment with a demethylating agent restored GTL2 expression and reduced DLK1 expression. As described for IGF2/H19, epigenetic changes at DLK1/GTL2 occur in human cancers. However, these changes are not associated with DLK1 LOI highlighting differences in the imprinting control mechanisms operating in the IGF2-H19 and DLK1-GTL2 domains. GTL2 promoter and intergenic DMR hypermethylation is associated with the loss of GTL2 expression and this may contribute to tumorigenesis in a subset of human cancers.

PubMed Disclaimer

Figures

Figure 1

Figure 1

(A) Methylation-specific multiplexed PCR of the DMR upstream GTL2 promoter in neuroblastoma cell lines showing the presence of only methylated allele of 160 bp. M+ is in vitro methylated DNA. (B) Normal blood DNA was used as control showing both unmethylated (120 bp) and methylated (160 bp) allele. (C) RT–PCR analysis of DLK1 and GTL2 in four neuroblastoma cell lines before (−) and after (+) treatment with demethylating agent 5-AzaC. DLK1 expression was reduced, while GTL2 expression was activated following 5-AzaC treatment. Molecular weight marker was a 100-bp ladder (Invitrogen).

Figure 2

Figure 2

Analysis of DLK1 allele expression in the informative SK-N-AS cell line. DLK1 is monoallelically expressed before and following treatment with 5-AzaC.

Figure 3

Figure 3

RT–PCR showing GTL2 expression in neuroblastoma tumours without gain of methylation at 5′ GTL2 DMRs (lanes 1–6) and tumour with gain of methylation at 5′ GTL2 DMRs (lane 7). Low level of GTL2 expression in this tumour may be caused by normal tissue contamination. Lane 8 is a negative control and GAPDH was used as unlinked control gene.

Figure 4

Figure 4

(A) Schematic representation of GTL2 and IG-DMRs in human showing the position of regions analysed: G1=−363 bp → −161 bp upstream, G2=+293 bp → +673 bp downstream, and G3=+1213 bp → +1583 bp downstream of GTL2 transcription start site, GeneBank accession no. AY314975; IG-DMR=nt 51021–51180, GeneBank accession no. AL 117190). (B) Methylation status of the CpGs in the IG-DMR in the normal blood, neuroblastoma cell lines, a Wilms' tumour, two neuroblastoma tumours and a phaeochromocytoma tumour with gain of methylation at the 5′ GTL2 DMRs. (C) Methylation status of GTL2 DMRs in neuroblastoma cell lines. The methylation status is shown in circles. Open and filled circles indicates complete unmethylation and full methylation, respectively. Partially filled circles indicate the degree of partial methylation.

Similar articles

Cited by

References

    1. Charlier C, Segers K, Karim L, Shay T, Gyapay G, Cockett N, Georges M (2001) The Callipyge mutation enhances the expression of coregulated imprinted genes in cis without affecting their imprinting status. Nat Genet 27: 367–369 - PubMed
    1. Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenkov VV, Feinberg AP (2001) Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 61: 4947–4950 - PubMed
    1. Eggermann T, Mergenthaler S, Eggermann K, Albers A, Linnemann K, Fusch C, Ranke MB, Wollmann HA (2001) Identification of interstitial maternal uniparental disomy (UPD) (14) and complete maternal UPD(20) in a cohort of growth retarded patients. J Med Genet 38: 86–89 - PMC - PubMed
    1. Feinberg AP, Cui H, Ohlsson R (2002) DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 12: 389–398 - PubMed
    1. Freking BA, Murphy SK, Wylie AA, Rhodes SJ, Keele JW, Leymaster KA, Jirtle RL, Smith TP (2002) Identification of the single base change causing the Callipyge muscle hypertrophy phenotype, the only known example of polar overdominance in mammals. Genome Res 12: 1496–1506 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources